Aptevo Therapeutics Inc. (APVO): Cash & Equivalents
$21.62M
As of 2025-12-31
$9.80M
As of 2026-06-30
-1.5%
3-year compound annual growth
-11.6%
5-year compound annual growth
+16.6%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.62M | +148.1% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $8.71M | -48.5% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $16.90M | -25.3% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $22.64M | -49.7% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $45.04M | +12.7% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $39.98M | +221.2% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $12.45M | -59.4% | 2021-03-31, Balance as of period end |
| 2018-12-31 | $30.64M | +331.8% | 2020-03-25, Balance as of period end |
| 2017-12-31 | $7.09M | -26.7% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $9.68M | +108.7% | 2018-03-13, Balance as of period end |
| 2015-12-31 | $4.64M | n/a | 2017-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $21.62M | +148.1% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $3.62M | -71.4% |
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $5.88M | -91.4% |
| BeyondSpring Inc. (BYSI) | 2025-12-31 | $7.79M | +166.5% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $6.39M | +8.2% |
| Elicio Therapeutics, Inc. (ELTX) | 2025-12-31 | $18.56M | +5.4% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $3.62M | +115.6% |
Compare APVO, HURA, SKYE, BYSI side by side · Screen every company in Pharmaceutical Preparations ↗